The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore

J Pharmacol Exp Ther. 2002 Nov;303(2):858-66. doi: 10.1124/jpet.102.036350.

Abstract

Marine natural products provide a rich source of chemical diversity that can be used to design and develop new, potentially useful therapeutic agents. We report here that scytonemin, a pigment isolated from cyanobacteria, is the first described small molecule inhibitor of human polo-like kinase, a serine/threonine kinase that plays an integral role in regulating the G(2)/M transition in the cell cycle. Scytonemin inhibited polo-like kinase 1 activity in a concentration-dependent manner with an IC(50) of 2 microM against the recombinant enzyme. Biochemical analysis showed that scytonemin reduced GST-polo-like kinase 1 activity in a time-independent fashion, suggesting reversibility, and with a mixed-competition mechanism with respect to ATP. Although scytonemin was less potent against protein kinase A and Tie2, a tyrosine kinase, it did inhibit other cell cycle-regulatory kinases like Myt1, checkpoint kinase 1, cyclin-dependent kinase 1/cyclin B, and protein kinase Cbeta2 with IC(50) values similar to that seen for polo-like kinase 1. Consistent with these effects, scytonemin effectively attenuated, without chemical toxicity, the growth factor- or mitogen-induced proliferation of three cell types commonly implicated in inflammatory hyperproliferation. Similarly, scytonemin (up to 10 microM) was not cytotoxic to nonproliferating endotoxin-stimulated human monocytes. In addition, Jurkat T cells treated with scytonemin were induced to undergo apoptosis in a non-cell cycle-dependent manner consistent with its activities on multiple kinases. Here we propose that scytonemin's dimeric structure, unique among natural products, may be a valuable template for the development of more potent and selective kinase inhibitors used for the treatment of hyperproliferative disorders.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • CDC2 Protein Kinase / antagonists & inhibitors
  • Cell Cycle Proteins
  • Cell Division / drug effects
  • Cyclic AMP-Dependent Protein Kinases / metabolism
  • Cyclin B / antagonists & inhibitors
  • Enzyme Inhibitors / pharmacology*
  • Glutathione Transferase / antagonists & inhibitors
  • Glutathione Transferase / metabolism
  • Humans
  • Indoles / isolation & purification
  • Indoles / pharmacology*
  • Jurkat Cells
  • Kinetics
  • Phenols / isolation & purification
  • Phenols / pharmacology*
  • Polo-Like Kinase 1
  • Protein Kinase C / metabolism
  • Protein Kinase Inhibitors*
  • Protein Kinases*
  • Protein Serine-Threonine Kinases
  • Proto-Oncogene Proteins

Substances

  • Antineoplastic Agents
  • Cell Cycle Proteins
  • Cyclin B
  • Enzyme Inhibitors
  • Indoles
  • Phenols
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins
  • scytonemin
  • Glutathione Transferase
  • Protein Kinases
  • Protein Serine-Threonine Kinases
  • Cyclic AMP-Dependent Protein Kinases
  • Protein Kinase C
  • CDC2 Protein Kinase